Purpose/Objective: Uterine cervical carcinoma is still remaining one of the main mortality reasons for female population in the developing world. Inspite of widely accessible screening and diagnostic procedures in the vast majority of cases in our country cervical cancer is revealed in locally advanced stages with metastasis in pelvic and paraaortal lymph nodes in up to 34% of patients. Concurrent chemoradiotherapy is the treatment of choice for cervical cancer today but the presence of positive lymph nodes require escalation of EBRT dose to these targets. The aim of this research was analysis of treatment results of 62 node positive cervical cancer patients.
Purpose/Objective: Treatment of locally advanced cervical cancer combines chemotherapy, EBRT and intracavity brachytherapy. Differing dose and fractionation schedules exist for the use of intracavity brachytherapy in cervical carcinoma. Following the switch from MDR to HDR in 2007, treatment within our centre was directed by ABS guidelines involving 30Gy in 5 fractions until 2010. From 2010 onwards due resource availability an altered schedule of 24Gy in 4 fractions was implemented. We sought to analyse and compare outcomes for these two regimens. Materials and Methods: A retrospective analysis of treatment and outcomes was conducted for patients receiving primary chemo radiation for cervical carcinoma between Nov 2007 -Feb 2009 and Feb 2010 -Feb 2011 Overall survival and recurrence rates were analysed using Kaplan Meier survival analysis. Late toxicity was assessed according to RTOG/EORTC Late Morbidity Scoring Scheme. Results: 123 patients were identified. Patients received pelvic EBRT to a dose of 4500cGy in 25 fractions with a combination of platinum based induction or concomitant chemotherapy schedules followed by intracavity HDR brachytherapy. 59 patients received 3000cGy in 5 fractions (Group A) and 64 patients received 2400cGy in 4 fractions (Group B) of HDR intracavity brachytherapy. Patient characteristics were comparable between Group A and B, median age 48 (range 24 -76) and 50 years (range 30 -88) respectively. Squamous cell carcinoma was the most commonly observed histological subtype in both groups. Local control rates at 3 years are 75% and 81.6% for Group A and B respectively. Distant control at 3 years for Group A is 72.5% compared to 84.7% in Group B. There was no significant difference in PFS between Groups (log rank p = 0.16). OS at 3 years in Group A was 58% compared to 73% in Group B (log rank p = 0.059). The rate of fistula development was 6.8% and 4.7% for Group A and B respectively. Late G3 /4 toxicity rates in Group A were reported as 10.2% compared with 6.25% in Group B. Conclusions: A reduced dose fractionation schedule to 2400cGy in 4 fractions is safely deliverable when compared to 3000cGy in 5 fractions. There is no increase in recurrence or late toxicity seen in our patient group. It may be a preferable treatment delivery schedule resulting in reduced theatre time, reduced number of insertions and anaesthesia requirement.
EP-1266
Interstitial brachytherapy using MUPIT in locally advanced or recurrent gynecological malignancies H. Letelier 1 , C. Gutiérrez 2 , E. Martínez 2 , M. Galdeano 2 , S. Marín 2 , J. Pera 2 , S. Moreno 2 , F. Pino 2 , F. González 2 , M. García 2 , F. The purpose of this study was to assess characteristics, treatment outcomes and complications in patients with locally advanced or recurrent gynecological malignancies treated with interstitial brachytherapy using MUPIT.
Materials and Methods:
We performed a retrospective review of all patients with gynecological malignancies treated with MUPIT in a single institution between January 2005 and May 2014. Cases without data or follow up were excluded. Information recorded were demographic and clinic characteristics, previous use of RT (external or BT), dose rate of interstitial BT, local control rate, late toxicity and mortality rate. Categorical variables are presented as frequencies and proportions, and continuous variables as the mean, median, and range. Local recurrence-free survival (LRFS) and overall survival (OS) after MUPIT treatment were estimated using the Kaplan-Meier method. Results: Forty six patients were identified. The median age was 64 years (range, 28 -85). Cervical and endometrial cancers were the most common primary site, with 20 and 16 cases respectively. The indications of interstitial BT were treatment of local recurrence (31), primary tumor (14) and metastases (1). Forty patients received external RT or BT before interstitial BT. High dose rate BT was used in 37 cases. Median LRFS was 76.2 months (CI 95% 61.6 -90.7) and the median survival time was 82 months (CI 95% 67.5 -96.5). There have been no cases of Grade IV late toxicity. Proctitis and pelvic pain were the most common grade III complications (4 patients). Conclusions: Interstitial BT using MUPIT applicator is an effective treatment which obtains high rates of local control despite the bad prognosis of pelvic recurrencies. Secondary effects are few, and manageable.
EP-1267
Defining a standard method for functional bone marrow sparing with IMRT for cervical cancer K. Morrison 1 , I. Zerizer 2 , R. Trouncer 1 , I. Murray 2 , K. Amin 1 , A. Taylor 1 1 Royal Marsden Hospital, Radiotherapy, London, United Kingdom 2 Royal Marsden Hospital, Imaging, London, United Kingdom Purpose/Objective: Bone marrow sparing using intensitymodulated radiotherapy (IMRT) could reduce haematological toxicity from radical chemoradiation for cervical carcinoma. One challenge is to determine the location of functioning bone marrow rather than attempt to spare the whole bony pelvis. On FDG-PET the areas of higher activity correlate with SUV values, and the scans used to stage disease could potentially be used to also identify functioning bone marrow. The aims of this study were to identify functioning pelvic bone marrow using FDG-PET, to analyse the pattern of distribution between patients and to develop guidelines for defining bone marrow as an organ at risk which can be applied to radiotherapy CT scans for all patients. Materials and Methods: The FDG-PET scans from 10 patients treated for cervical cancer were assessed. Structure sets consisting 6 absolute SUV thresholds (0.5,1.0, 1.5, 2.0, 2.5 and 3.0) were created. The distribution of SUV activity within each pelvic subregion and the whole bony pelvis was analysed. The maximum SUV value within the bony pelvis (SUVmax) was defined as the highest level with a volume > 1cc. Volumetric data for SUVMax, SUV >75%Max (SUV75) and SUV>50%Max (SUV50) were compared, measuring the contribution to each region and to the total activity. Results: The absolute SUV values within the pelvis varied between patients whereas relative values were more comparable. A reproducible pattern of distribution was evident in all patients using SUV75. The highest activity is seen within the lumbar spine, sacrum, posterior iliac alae and pubic bone contributing 86.67% total activity. For SUV75, the SUV range was 1.0 -2.5 with a mean volume of 98.9cc SD 50.3) , which is 6.9% (range 1.7 -12.9, SD 3.2) of the mean total pelvic volume. Conclusions: There is a reproducible pattern of functional bone marrow on FDG-PET within the pelvis. Guidelines for contouring a standard avoidance structure on the planning CT scan have been generated which encompass the areas of highest activity. Bone marrow avoidance should be assessed further in dosimetric and clinical studies.
